Cullinan Therapeutics (CGEM) Accumulated Depreciation (2020 - 2025)

Cullinan Therapeutics' Accumulated Depreciation history runs 6 years deep, the most recent figure standing at $969000.0 for Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 47.26% year-over-year to $969000.0 in Q4 2025; TTM through Dec 2025 was $969000.0, a 47.26% increase from a year earlier, with the FY2025 full-year figure at $969000.0, up 47.26% from the prior year.
• Accumulated Depreciation grew to $969000.0 in Q4 2025 per CGEM's latest filing, from $658000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $969000.0 in Q4 2025 and bottomed at $135000.0 in Q4 2022.
• The 5-year median for Accumulated Depreciation is $352000.0 (2023), against an average of $469200.0.
• Across the five-year window, Accumulated Depreciation sank 41.81% in 2022 and surged 160.74% in 2023, its largest moves.
• Year by year, Accumulated Depreciation stood at $232000.0 in 2021, then sank by 41.81% to $135000.0 in 2022, then soared by 160.74% to $352000.0 in 2023, then surged by 86.93% to $658000.0 in 2024, then surged by 47.26% to $969000.0 in 2025.
• Per Business Quant, the three latest CGEM Accumulated Depreciation figures stand at $969000.0 (Q4 2025), $658000.0 (Q4 2024), and $352000.0 (Q4 2023).